SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK Crypto is trending as its highly engaged community rallies behind its unique narrative to challenge traditional retirement systems. Recent excitement is driven by its appearance in a major exchange's presentation and upcoming marketing campaigns, with many holders showcasing strong conviction through staking and a shared belief in its long-term potential.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as it navigates a contentious potential acquisition of Warner Bros. Discovery, which faces an escalating rival bid from Paramount/Skydance and looming regulatory scrutiny from the Trump administration. This high-stakes M&A drama is sparking intense debate among investors, with many frustrated by the stock's recent downtrend and concerns over debt, while others view current price levels as an oversold opportunity ahead of upcoming earnings.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics, positioning it as the foundational "meme reset" for an upcoming market cycle. This dedicated base is consistently building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and leadership in the meme coin space, and urging others to "Return to the Memes" and "Rage On."

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending due to its escalating hostile takeover bid for Warner Bros. Discovery (WBD), having reiterated its all-cash offer and initiated a lawsuit seeking financial disclosures from WBD. The community is actively debating the superior value of PSKY's bid over Netflix's alternative, with much discussion centered on WBD's board resistance and the broader implications for media industry consolidation and regulatory hurdles.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as community discussions center on recent statements regarding big tech's responsibility for data center electricity costs, fueling debate around future AI infrastructure investments. While some view current price action as underperforming, others see it as an accumulation opportunity ahead of upcoming earnings amid the broader context of intense AI competition and power demand for cloud services.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is actively discussed amidst its presence at a major healthcare conference, highlighted by the strategic appointment of a Chief Commercial Officer and completed enrollment in a key obesity maintenance study for VK2735. The community is eagerly anticipating regulatory clarity for its oral VK2735 to advance directly to Phase 3, alongside pervasive speculation around potential partnerships or a lucrative buyout. This excitement stems from the drug's perceived best-in-class profile and strong differentiation in the rapidly expanding GLP-1/GIP agonist market.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following cautious 2026/2027 revenue guidance, largely driven by the anticipated impact of DefenCath's reimbursement shift in mid-2026, which triggered a sharp sell-off. The community is deeply divided, with many calling the plunge an "overreaction" and a buying opportunity given strong institutional ownership and pipeline potential. Others express frustration with management, viewing the guidance as conservative while anticipating future catalysts like the Kidney Care Access Protection Act and REZZAYO trial data.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending due to significant market volatility surrounding its FILSPARI sNDA for FSGS, following an FDA request for additional clinical benefit data. While some anticipate a Complete Response Letter and further declines, many investors view the sharp sell-off as an exaggerated reaction, highlighting strong existing product sales and cash reserves as a buying opportunity. The immediate focus is on the regulatory outcome for this label expansion, which contrasts with the drug's robust performance in its IgAN indication.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix is trending sharply upward following its preliminary Q4 and full-year 2025 results, which reported strong revenue growth and reaffirmed positive adjusted EBITDA guidance. The community is actively discussing sustained momentum and further price appreciation, although some investors express caution regarding the company's cash position and potential future share dilution. This intense speculative interest, evidenced by massive trading volume, centers around the precision lung diagnostics firm.

Didi Global, Inc. engages in the operation of mobility platforms that provides ride hailing and other related services. It operates through the following segments: China Mobility, International, and Other Initiative. The China Mobility segment consists of ride hailing, taxi hailing, chauffeur and hitch services. The International segment includes ride hailing and food delivery services in international markets, outside of China. The Other Initiatives segment mainly consists of bike and e-bike sharing, certain auto solutions, intra-city freight, community group buying, autonomous driving, and financial services. The company was founded by Wei Cheng, Qing Liu, Bo Zhang and Rui Wu on January 11, 2013 and is headquartered Beijing, China.

DiDi Global Inc - ADR

DiDi Global is trending as investors eagerly await the finalization of its class-action lawsuit settlement, a critical step many believe will clear the path for a highly anticipated Hong Kong listing. The community is also buzzing about strategic AI partnerships and significant strides in autonomous driving, including a 24/7 driverless Robotaxi service rollout, amidst ongoing frustrations over persistent price volatility and perceived market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to...

Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving Average - Should You Sell?

Verastem (NASDAQ:VSTM) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell...

Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.read more...

<ul class="summary-bullets"><li>While the discontinued trial yielded early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Verastem CMO said.&nbsp;</li><li>Verastem said it will now focus its resources on the clinical development of VS-7375 in advanced NSCLC and other solid tumors.&nbsp;</li><li>VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.</li></ul> Shares of Verastem Oncology (VSTM) fell 2% after hours on Monday after the company said that it has decided to discontinue its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.No more patients will be enrolled in the trial being conducted in collaboration with Amgen and those already enrolled can continue treatment as per the investigator's discretion, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251229302295/en/Verastem-Oncology-Provides-Update-on-RAMP-203-Phase-12-Clinical-Trial-for-Advanced-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer">said</a>. The trial was evaluating Avutometinib and Amgen’s Sotorasib in a “doublet combination” and also with Defactinib as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor, which is a targeted cancer drug that block the specific KRAS G12C mutation.The company said it is assessing opportunities to share data from the interim analysis in the future. &nbsp;<h2 class="st-heading-2">Fresh Focus</h2>Verastem said it will now focus its resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors while also evaluating Avutometinib plus Defactinib in combination with chemotherapy in first line metastatic pancreatic cancer.“While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates,” chief medical officer John Hayslip said.Hayslip added that VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VSTM jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘low’ levels.A Stocktwits user applauded the decision as “sound.”<stembedurl>https://www.stocktwits.com/Drew613/message/640355285</stembedurl>Another opined that the VS-7375 numbers are “very exciting” and said they could see why the company prioritized it over the discontinued trial.<stembedurl>https://www.stocktwits.com/Sawnchey/message/640352752</stembedurl><a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained 50% this year and more than doubled over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 

Equity

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 


Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of...

Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM

Squarepoint Ops LLC increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 2,995.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The...

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat Ratings reports. One...

Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 2,000 Shares of Stock

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average...

Verastem (NASDAQ:VSTM) CEO Dan Paterson Sells 2,000 Shares

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of Verastem stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $10.07...

BVF Inc. IL Raises Stock Position in Verastem, Inc. $VSTM

BVF Inc. IL grew its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 62.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$7.11
Prev Close	$7.79
Open	$7.74
Dividend Yield	0.00%
50-Day Moving Average	$8.77
Beta	1.38
Avg. Volume	1.71M
PE Ratio	-1.67

52-Week High	$11.25
52-Week Low	$4.01
Market Capitalization	$586.74M
EPS (Annual)	-$3.66
Price to Book	-30.57
Revenue Per Employee	$128,205.13
Enterprise Value/EBITDA	N/A

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc